Wire · opportunities
QIAGEN Expands US QIAstat-Dx Portfolio With New FDA-Cleared Panel
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 3 October 2026 · Fusion42 review
QIAGEN received FDA clearance for its new QIAstat-Dx BCID GN Plus AMR Panel, expanding rapid bloodstream infection testing in the US to cover key gram-negative bacteria and antibiotic resistance markers, complementing its existing gram-positive and fungal panel.
This Wire brief sits within Fusion42's coverage of Diagnostics.
◆ ◆ The Wire takeaway
You can now offer US labs a broader rapid test that identifies crucial gram-negative bacteria and resistance markers within an hour. Rapid infectious disease diagnostics just opened a new door for labs and treatment decision tools, speeding critical care.
◆ Coverage
1 source · 2 Oct 2026
◆ Related on Wire
◆ Topics